New Delhi: India’s Biocon Biologics closed the 12 months to end-March with revenue on a trajectory in direction of $1 billion, its CEO stated on Wednesday, helped by robust gross sales within the US and Europe from the biosimilars enterprise it purchased final 12 months from Viatris Inc.
Biocon Biologics, which acquired the biosimilars enterprise of US-based Viatris in a $3.34 billion deal, stated its annual revenue rose 61 per cent year-on-year to 55.84 billion rupees, reflecting one quarter of consolidated figures after the purchase, in comparison with 34.64 billion rupees the earlier 12 months.
“This has been a landmark 12 months for Biocon Biologics,” Shreehas Tambe, the CEO of Biologics stated after its Indian mother or father Biocon posted January-March outcomes on Tuesday.
The world marketplace for biosimilars, that are copies of extra expensive organic medication used to deal with diseases reminiscent of rheumatoid arthritis and most cancers, is anticipated to greater than triple to $74 billion by 2030, McKinsey forecasts.
Revenue from biosimilars greater than doubled to 21.02 billion rupees ($257 million) within the quarter, which marked the primary full quarter of consolidated financials because the buy.
Industry estimates predict greater than 55 model identify blockbuster biologic medication, every with peak annual gross sales above $1 billion, are because of come off patent by the top of the last decade.
Tambe stated Biologics launched greater than 35 merchandise final 12 months, lifting its revenues and increasing its world attain.
Biologics plans to launch Hulio (bAdaminumab), a biosimilars model of AbbVie’s blockbuster Humira, within the US market in July, with estimated world market of greater than $18 billion for the arthritis drug, Tambe added.
The firm invested greater than 16 per cent of its revenue in analysis and growth of recent medication, amounting to eight.9 billion rupees ($109 million) in its final fiscal 12 months, and hopes to earmark 12 per cent of revenue for R&D over the medium time period.
